Amid complaints from shareholder activists, Endo International (ENDP) has issued a report about the risks of selling opioid painkillers and agreed to expand a so-called clawback policy for executive compensation when negligence occurs. The company will also beef up disclosure of its lobbying efforts.

The move is the latest victory for Investors for Opioid Accountability, a coalition of institutional investors that has been pushing drug makers, wholesalers, and pharmacies to take steps to rein in the opioid crisis by changing business practices. Previously, Assertio Therapeutics (ASRT) agreed to monitor opioid risks, but Endo is the first large drug maker to take a more comprehensive step.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy